Lexicon outlines 2026 milestones as SONATA-HCM enrollment surpasses 50% and cash position is strengthened
Source: SeekingAlpha
2026-03-05 17:16:39 ET
More on Lexicon Pharmaceuticals
- Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript
- Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward
- Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Lexicon Pharma spikes after insider buy
- Lexicon Pharmaceuticals prices $94.6M share offering
Read the full article on Seeking Alpha
For further details see:
Lexicon outlines 2026 milestones as SONATA-HCM enrollment surpasses 50% and cash position is strengthened
Lexicon Pharmaceuticals Inc.
NASDAQ: LXRX
LXRX Trading
1.52% G/L:
$1.675 Last:
1,322,736 Volume:
$1.66 Open:
LXRX Latest News
March 11, 2026 08:00:00 am
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
March 05, 2026 06:59:00 am
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
LXRX Stock Data
$557,345,360
216,958,960
0.2%
137
N/A
Biotechnology & Life Sciences
Healthcare
US
The Woodlands
